Pharma Equity Group ASOCSE:PEG +2.33% Current Ratio is 4.33 as of Dec. 2025, which is 0% below its 10-year median of 4.34. The stock has 3 warning signs investors should review. Among 1,412 Biotechnology companies, Pharma Equity Group AS ranks better than 53.4% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pharma Equity Group AS's current ratio for the quarter that ended in Dec. 2025 was 4.33.
Pharma Equity Group AS has a current ratio of 4.33. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Pharma Equity Group AS's Current Ratio or its related term are showing as below:
OCSE:PEG'
s Current Ratio Range Over the Past 10 Years
Min: 0.01 Med: 4.34 Max: 71.38
Current: 4.33
During the past 13 years, Pharma Equity Group AS's highest Current Ratio was 71.38. The lowest was 0.01. And the median was 4.34.
OCSE:PEG's Current Ratio is ranked better than 53.4% of 1412
companies
in the Biotechnology industry
Industry Median: 3.9
vs OCSE:PEG: 4.33
Pharma Equity Group AS (OCSE:PEG) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pharma Equity Group AS Current Ratio Related Terms
Pharma Equity Group AS Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OCSE:PEG vs VRTX, REGN, ALNY: Current Ratio Comparison
For the Biotechnology subindustry, Pharma Equity Group AS's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharma Equity Group AS Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pharma Equity Group AS's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharma Equity Group AS (OCSE:PEG) has a Current Ratio of 4.33 as of Dec. 2025. This is near median its historical median of 4.34. Over the past decade, Pharma Equity Group AS's Current Ratio has ranged from 0.01 to 71.38. According to the industry distribution chart, Pharma Equity Group AS ranks #658 out of 1412 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Pharma Equity Group AS's Current Ratio too high?
Pharma Equity Group AS's current Current Ratio of 4.33 is near median its 10-year median of 4.34. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 71.38. The Biotechnology industry median Current Ratio is 3.90. Pharma Equity Group AS's value of 4.33 is 11% above this industry median. Based on the distribution chart, Pharma Equity Group AS ranks #658 out of 1412 companies in the Biotechnology industry, which is above the industry midpoint.
How does Pharma Equity Group AS's Current Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharma Equity Group AS ranks #658 out of 1412 companies for Current Ratio. This puts Pharma Equity Group AS in the upper half of its industry. The industry median Current Ratio is 3.90. Pharma Equity Group AS's value of 4.33 is 11% above this benchmark. Historically, Pharma Equity Group AS's own Current Ratio has ranged from 0.01 to 71.38 over the past decade. While the company's 10-year median is 4.34 vs. the industry median of 3.90, Pharma Equity Group AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.90, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharma Equity Group AS's current Current Ratio of 4.33 is 11% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharma Equity Group AS's current Current Ratio is 4.33, which is near median its own 10-year median of 4.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharma Equity Group AS stock overvalued right now?
Pharma Equity Group AS (OCSE:PEG) has a current Current Ratio of 4.33. The current Current Ratio is 4.33, which is near median its 10-year median of 4.34 and 11% above the Biotechnology industry median of 3.90. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pharma Equity Group AS (OCSE:PEG), the current Current Ratio is 4.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OCSE:PEG has been successfully added to your 